Merck to Acquire Terns Pharmaceuticals via Subsidiary for $53 Cash Offer
Merck (MRK) is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals (TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. Following the purchase of shares in the tender offer, Terns will become a wholly owned subsidiary of Merck. Merck has filed today with the U.S. Securities and Exchange Commission a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Terns has filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of the Terns board of directors that their stockholders accept the tender offer and tender their shares. The tender offer will expire one minute following 11:59 p.m., Eastern Time, on May 4, 2026, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to certain conditions, including the tender of shares representing more than 50% of the total number of Terns' outstanding shares, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions. The transaction is expected to close in the second quarter of 2026.
Trade with 70% Backtested Accuracy
Analyst Views on MRK
About MRK
About the author
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
FDA Approves Merck's Idvynso for HIV Treatment
- New Drug Approval: The US FDA has approved Merck's Idvynso, a single-pill regimen combining Pifeltro (doravirine) and islatravir, marking a significant advancement in HIV treatment options.
- Innovative Mechanism: Doravirine acts as a non-nucleoside reverse transcriptase inhibitor, while islatravir is a novel nucleoside reverse transcriptase translocation inhibitor that halts HIV-1 replication by inhibiting reverse transcriptase translocation and inducing structural changes in viral DNA, showcasing its unique therapeutic mechanism.
- Clinical Trial Support: The approval is based on the results of two randomized, non-inferior trials demonstrating that Idvynso is comparable in efficacy to Gilead's Biktarvy, enhancing its competitive position in the market.
- Market Potential: With the ongoing demand for HIV treatments, the launch of Idvynso not only provides patients with a new therapeutic option but also has the potential to generate significant revenue growth for Merck in a highly competitive pharmaceutical landscape.
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
FDA Grants Approval for Merck's Once-Daily IDVYNSO™ (Doravirine/Islatravir)
FDA Approval: The FDA has approved Merck's once-daily oral antiviral medication, known as Islatravir, for the treatment of HIV.
Medication Details: The drug is marketed under the name DORAVIRINE and is designed to simplify HIV treatment regimens for patients.
Merck & Co Inc: FDA Establishes PDUFA Action Date for August 17, 2026
- Merck & Co. Announcement: Merck & Co. has set a target action date of August 17, 2026, for its product under review by the FDA.
- FDA Review Process: The announcement indicates that the FDA is currently evaluating Merck's submission, with a decision expected by the specified date.
FDA Approves Priority Review for Keytruda® and Keytruda Qlex™ in Combination with Padcev® for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin
FDA Grants Priority Review: The FDA has granted priority review for two drugs, Keytruda® (pembrolizumab) and Keytruda QLEX™ (pembrolizumab and berahyaluronidase), aimed at treating muscle-invasive bladder cancer.
Indication for Eligible Patients: These treatments are specifically for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.
FDA Approves Merck's Idvynso for HIV Treatment
- New Drug Approval: The US FDA has approved Merck's Idvynso, a single-pill regimen combining Pifeltro (doravirine) and islatravir, marking a significant advancement in HIV treatment options.
- Innovative Mechanism: Doravirine acts as a non-nucleoside reverse transcriptase inhibitor, while islatravir is a novel nucleoside reverse transcriptase translocation inhibitor that halts HIV-1 replication by inhibiting reverse transcriptase translocation and inducing structural changes in viral DNA, showcasing its unique therapeutic mechanism.
- Clinical Trial Support: The approval is based on the results of two randomized, non-inferior trials demonstrating that Idvynso is comparable in efficacy to Gilead's Biktarvy, enhancing its competitive position in the market.
- Market Potential: With the ongoing demand for HIV treatments, the launch of Idvynso not only provides patients with a new therapeutic option but also has the potential to generate significant revenue growth for Merck in a highly competitive pharmaceutical landscape.
FDA Approves IDVYNSO for HIV Treatment in Adults
- FDA Approval: IDVYNSO has received FDA approval as the first non-INSTI, tenofovir-free, once-daily two-drug regimen, demonstrating non-inferior efficacy compared to the three-drug regimen BIKTARVY, marking a new option in HIV treatment that may enhance patient adherence.
- Clinical Trial Data: In two randomized controlled non-inferiority trials involving 708 HIV patients, only 1% of those on IDVYNSO had HIV-1 RNA ≥50 copies/mL at Week 48, indicating its effectiveness in maintaining viral suppression comparable to BIKTARVY.
- Diverse Patient Population: Among trial participants, 11% were aged 65 and older, showcasing IDVYNSO's applicability in older patients, with similar treatment outcomes across different age, sex, and racial groups, enhancing its market potential.
- Safety and Tolerability: The safety profile of IDVYNSO was comparable to BIKTARVY, with only 3% of patients discontinuing due to adverse events at Week 48, and common side effects like diarrhea and headache were low, indicating good tolerability that may facilitate broader clinical use.
Merck and Eisai's Late-Stage Trial Fails to Meet Goals
- Trial Outcome: The LITESPARK-012 trial conducted by Merck and Eisai failed to meet its primary endpoints of progression-free survival (PFS) and overall survival (OS) in kidney cancer patients, which could negatively impact future treatment strategies for both companies.
- Patient Enrollment: Over 1,600 patients were enrolled in the trial, testing various drug combinations including Keytruda and Lenvima, but failed to demonstrate superiority over the already approved Keytruda plus Lenvima regimen, indicating a lack of efficacy for the new therapies.
- Safety Profile: Although the combination therapies did not meet the primary endpoints, the companies noted that their safety profiles were consistent with past results for individual drugs, suggesting no new significant risks emerged, which still holds some value for future clinical applications.
- Market Implications: The failure of this trial may affect Merck's market position in kidney cancer treatment, especially ahead of the Keytruda patent cliff, forcing the company to accelerate other R&D projects to maintain competitiveness.
